TABLE A2.
EORTC QLQ-HCC18 Compliance Rates
| Week | Compliance Rate, % | ||
|---|---|---|---|
| STRIDE (n = 393) | Durvalumab (n = 389) | Sorafenib (n = 389) | |
| Baseline | 77.1 | 83.6 | 87.5 |
| Overall | 72.7 | 82.8 | 80.8 |
| 8 | 86.1 | 89.1 | 82.7 |
| 16 | 73.3 | 77.4 | 68.6 |
| 24 | 71.8 | 69.4 | 68.6 |
| 32 | 73.3 | 71.3 | 75.2 |
| 40 | 67.9 | 67.8 | 64.0 |
| 48 | 69.7 | 76.6 | 70.8 |
| 60 | 65.5 | 80.2 | 51.3 |
| 72 | 74.5 | 71.3 | 60.7 |
| 84 | 67.0 | 73.6 | 73.6 |
| 96 | 70.7 | 69.5 | 56.8 |
| 108 | 66.7 | 68.6 | 63.9 |
| 120 | 70.0 | 70.7 | 59.1 |
| 132 | 75.0 | 71.4 | 71.4 |
| 144 | 65.4 | 66.7 | 63.6 |
| 156 | 100.0 | 63.6 | 75.0 |
| 168 | 120.0 | 83.3 | 0.0 |
| 180 | 66.7 | 50.0 | 0.0 |
| 192 | 0.0 | 0.0 | 0.0 |
NOTE. Baseline compliance rate was defined as the proportion of total participants with an evaluable baseline questionnaire. Overall compliance rate was defined as the proportion of total participants with an evaluable baseline questionnaire and at least one evaluable follow-up questionnaire. Compliance rate at each time point was defined as the proportion of participants still under PRO follow-up with an evaluable questionnaire.
Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; HCC, hepatocellular carcinoma; PRO, patient-reported outcome; QLQ-HCC18, 18-item HCC Health-Related Quality of Life Questionnaire; STRIDE, Single Tremelimumab Regular Interval Durvalumab.